Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Segment Information (Tables)

v3.7.0.1
Note 11 - Segment Information (Tables)
 9 Months Ended
Mar. 31, 2017
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
 
 
Quarter Ended
 
 
Nine Months Ended
 
 
 
March 31,
 
 
March 31,
 
 
 
2017
 
 
2016
 
 
2017
 
 
2016
 
Net sales:
                                
Biotechnology
   $
94,516
     $
81,386
     $
267,256
     $
232,984
  
Diagnostics
    
25,978
      
29,929
      
74,542
      
76,013
  
Protein Platforms
    
23,586
      
19,693
      
64,707
      
55,327
  
Intersegment
    
(43
)
    
(35
)
    
(80
)
    
(63
)
Consolidated net sales
   $
144,037
     $
130,973
     $
406,425
     $
364,261
  
Segment operating income:
                                
Biotechnology
   $
45,242
     $
45,133
     $
127,195
     $
124,436
  
Diagnostics
    
6,004
      
9,454
      
18,108
      
21,464
  
Protein Platforms
    
3,256
      
1,592
      
5,308
      
1,948
  
Subtotal reportable segments
    
54,502
      
56,179
      
150,611
      
147,848
  
Costs recognized on sale of acquired inventory
    
(3,136
)
    
(1,082
)
    
(11,205
)
    
(3,439
)
Amortization of acquisition related intangible assets
    
(11,689
)
    
(7,276
)
    
(33,504
)
    
(22,048
)
Acquisition related expenses
    
(2,691
)
    
(1,313
)
    
(17,792
)
    
(2,284
)
Stock based compensation
    
(3,974
)
    
(2,317
)
    
(11,219
)
    
(6,676
)
Corporate general, selling, and administrative
    
(707
)
    
(664
)
    
(2,999
)
    
(2,820
)
Consolidated operating income
   $
32,305
     $
43,527
     $
73,892
     $
110,581